Vigipharm
Vigipharm is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
Sponsor ENYO Pharma
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- Fifteen study centers were initiated, but 12 centers across the US, France, and Spain enrolled participants.
- The study enrolled 26 participants, exceeding the initially planned sample size of 20 to 24 participants.
These findings describe the trial, not the service provider’s performance or responsibility.
A double-blind, randomized, placebo-controlled, multicentric, phase II study in adult patients with amyotrophic lateral sclerosis (ALS) to assess efficacy, safety, tolerability and pharmacokinetics of multiple intravenous infusions of NX210c.
Sponsor Axoltis Pharma
- Start (EU)
- Latest update
- Estimated end
- Not reported
A study to Assess the Effect of Vonafexor on Kidney Function in Subjects With Impaired Renal Function and Suspected MASH
Sponsor ENYO Pharma
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Vigipharm?
The 2026-10-09 snapshot links Vigipharm to 3 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Safety management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Vigipharm?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Nephrology, Neurology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Vigipharm conducted?
The linked trials record locations in 3 countries, including Germany, France, Spain. These are trial locations, not confirmed office locations or countries where Vigipharm delivered services.
What can this page tell me about Vigipharm's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Vigipharm. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Vigipharm